Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Lung Neoplasms 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Pheochromocytoma 1Paraganglioma 1Papillary renal cell carcinoma, sporadic 1Pancreatic Ductal Adenocarcinoma 1Osteoradionecrosis 1Mouth Neoplasms 1Melanoma 1Hereditary leiomyomatosis and renal cell cancer 1Gliosarcoma 1Fallopian Tube Mucinous Adenocarcinoma 1Craniopharyngioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3olaparib 2lutetium Lu 177 dotatate 2gallium Ga 68 dotatate 2Fluorodeoxyglucose F18 26-fluorodopamine 2tipifarnib 1fluorodopa F 18 1fludarabine phosphate 1belzutifan 1Temozolomide 1Nivolumab 1Ipilimumab 1Interleukin-13 1Cyclophosphamide 1Contrast Media 1CTLA-4 Antigen 1Biopsy 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × Contrast Media × 90 days × Clear all
NCT04394858 2026-05-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
46 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡